← All stories
Markets
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK® Demand Carried into Third Quarter 2026 as Field Sales Expansion Efforts Con…
Covered by 1 outlet
All coverage · 1 article